North America

Thu
28
Mar

Cannabis offers promise as a treatment for endometriosis pain and other symptoms

Almost 180 million women around the world suffer from endometriosis, and those who use cannabis to help treat the painful related symptoms rave about the relief they feel. Not only do experts cite anecdotal reports from women of less physical discomfort, but also better sleep, less painful sex and emotional respite.

Thu
28
Mar

WeedMD looks to outdoor grow to boost cannabis production capacity

WeedMD Inc. (WMD.V) is looking to leapfrog its Canadian pot cultivation capacity after the Ontario-based cannabis producer recently applied to Health Canada to amend its licence to include outdoor cultivation.

If approved, WeedMD would join a select group of major Canadian cannabis producers who have turned to growing their legal marijuana in an outdoor setting, which is considerably cheaper than producing pot in an indoor or greenhouse facility.

“It’s a licensed property, so to add an amendment on the site was a relatively simple thing for us to do,” said Keith Merker, WeedMD chief executive officer, in a phone interview with BNN Bloomberg. “For us to maximize our production and revenue as a company, we take all options into consideration.”

Thu
28
Mar

Patients who use cannabis opt to up potency, not quantity over time

People with and without cancer were more likely, over time, to use a more potent form of medical cannabis with increasingly higher amounts of THC, notes a report published this week in the Journal of Palliative Medicine.

Over the course of the two-year study, “all types of patients increased their THC dose by approximately 0.20 mg per week,” yielding a corresponding increase in the THC:CBD daily ratio. “Compared with non-cancer patients, these trends were not different in the cancer group for THC daily dose, but there were less pronounced increases in the THC:CBD daily ratio over time among cancer patients,” reports the study abstract.

Thu
28
Mar

Opinion: Creeping complacency in marijuana-stock investing is a possible warning sign

Serious marijuana investors ought to pay attention to the complacency that’s creeping into the stock market. Historically when complacency abounds, stocks fall, unless there are new positive fundamental developments or new short-squeezes.

A lot of money is to be made in marijuana. However, there are times when it is important to preserve capital. Since I wrote “How to potentially become a marijuana millionaire, albeit carefully,” a lot of money has been made in marijuana stocks by following segmented money flows. Let’s explore the latest money flows in marijuana stocks with the help of a chart.

Wed
27
Mar

Aphria CEO confident of revenue surge, snubs Green Growth

Aphria Inc. plans to reach C$1 billion ($746 million) in revenue by the end of 2020 and doesn’t need the help of Green Growth Brands Inc. to do it, according to the pot firm’s new chairman.

Irwin Simon intends to boost revenue from an estimated C$209 million in the fiscal year that ends May 31, and achieve margins of at least 40 percent. His plan relies on increased production at Aphria’s Canadian operations, which are currently only running at about 18 percent of potential capacity as some await licenses and others ramp up, he said.

Aphria stock gained as much as 2.3 percent to C$13.16 a share at 9:36 a.m. in Toronto.

Wed
27
Mar

Think of pot companies more like disruptive tech startups: Cronos CEO

The head of Cronos Group Inc. doesn’t think it’s fair to view Canadian cannabis producers today as traditional publicly-traded companies.

Instead, he thinks it’s better to compare pot companies to the tech sector where generating meaningful revenue may be overshadowed by creating something more disruptive. That might explain why Cronos has a $9-billion valuation but only generated $5.6 million in the quarter, despite getting a $2.4 billion investment from tobacco maker Altria Inc. in December for a 45 per cent stake in the cannabis producer.

Wed
27
Mar

Food for thought: Edible products containing cannabis among drivers of global medical cannabis market to 2024

More consumption of legal cannabis in the developed market is expected to largely drive the global medical cannabis market from 2019 to 2024, notes a new report issued by Research and Markets.

“The market is expected to witness significant growth, owing to legalization in several countries and high demand for both medical and recreational purposes,” states a press release from the company that offers custom research services.

Wed
27
Mar

Cronos Group Inc. announces fourth quarter 2018 and full year 2018 results

Read full article here

Pages

Subscribe to RSS - North America